Xuhui Feng

In my role as a Senior Scientist at Bristol Myers Squibb in Brisbane, California, I designed and characterized PoC models, collaborated with cross-functional groups to contribute to project development, and worked with external partners to develop a cardiac-specific drug delivery platform. I also delivered analytical reports assessing potential external pipelines and unique delivery platforms.

In my role as a Scientist at Bristol Myers Squibb, I led the generation and characterization of disease models, identified potential targets for pipeline development, and evaluated E3 ligase mediated protein degradation in hearts. Additionally, I collaborated with BD to assess external CV or metabolism-related pipeline, showcasing my expertise in cardiometabolism and drug development.

• Defined molecular mechanisms underlying cardiomyopathy and heart failure • Identified potential drug targets for therapy of cardiomyopathy • Translated bench findings to clinical applications for impactful results

In my role as a Postdoctoral Researcher at IUPUI, I led efforts to define molecular mechanisms underlying cardiomyopathy and heart failure using a pressure overload model. Collaborating with Gilead Science, I evaluated the effects of blocking LOXL2 on cardiac fibrosis to identify potential drug targets. Committed to translating bench findings to clinical applications, I strive to make impactful contributions to the field of cardiology.

Clinical trial design and Drug development

Screen new specific ligands for nuclear receptor and provided new drug design strategies for treating metabolic diseases. A. discover that Ivermectin binds into FXR LBD in a unique mode by structural analysis and that Ivermectin treatment could result in decreases in serum glucose and cholesterol levels through binding into FXR LBD in a unique mode. B. Identify that Ionomycin as a new PPARγ ligand improve hyperglycemia and insulin sensitivity without weight gains in the mouse model of diabetes.